journal article·2019-12-04Open access

Effect of miR-21 on apoptosis in hepatoblastoma cell through activating ASPP2/p38 signaling pathway in vitro and in vivo

Lili Liu, Likun Wang, Xidong Li, Ping Tian, Hao Xu, Zenglian Li, Enqin Liu

Abstract

The objective of this study was to investigate the mechanism underlying miR-21-associated apoptosis in HB. In this study, HB and adjacent tissues were collected from patients with HB. RT-PCR, FISH, western blot, apoptosis assay, migration, invasion and wound healing assays, caspase activity assay, luciferase reporter assays, and xenografts mouse model were used to determine the effects of miR-21 on HB cell apoptosis. The results revealed that miR-21 was up-regulated in both HB cell and tissue and was associated with progression of HB. MiR-21 inhibitor enhanced the apoptosis level in HB cells. MiR-21 inhibitor showed reduced abilities of migration and invasion. ASPP2 was a target gene of miR-21. Inhibition of ASPP2 increased abilities of migration and invasion in HB cells. Furthermore, miR-21 inhibitor caused increased activity p-38 signaling. In a xenografts mouse model, miR-21 inhibitor could significantly suppress tumor growth in nude mice along with enhanced expressions of ASPP2 and p38. Taken together, the results suggest that upregulation of miR-21 is related to HB progression and miR-21-associated apoptosis in HB is mediated through ASPP2/p38 signaling pathway in vitro and in vivo. This study provides novel insight into the effects of miR-21 on HB apoptosis and clue to develop new therapies.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pathology, Linyi People's Hospital

Department of Infectious Diseases, Linyi People's Hospital

References (30)

Show source-provided references
1. 10.1053/j.sempedsurg.2011.10.01110.1053/j.sempedsurg.2011.10.011 ↗
2. Birch JM. Epidemiology of pediatric liver tumors, In Pediatric Liver Tumors. Berlin, Heidelberg: Springer; 2011. p. 15-26.
3. 10.1002/pbc.2421710.1002/pbc.24217 ↗
4. 10.1002/pbc.2274010.1002/pbc.22740 ↗
5. 10.2174/15665240978983912510.2174/156652409789839125 ↗
6. 10.1038/sj.onc.120990910.1038/sj.onc.1209909 ↗
7. 10.1073/pnas.090523410610.1073/pnas.0905234106 ↗
8. 10.1016/S1097-2765(01)00367-710.1016/S1097-2765(01)00367-7 ↗
9. 10.1080/104281902100004001710.1080/1042819021000040017 ↗
10. 10.1158/0008-5472.CAN-08-130510.1158/0008-5472.CAN-08-1305 ↗
11. 10.1007/s00247-006-0361-510.1007/s00247-006-0361-5 ↗
12. 10.7717/peerj-cs.6710.7717/peerj-cs.67 ↗
13. 10.1016/j.fct.2016.03.01310.1016/j.fct.2016.03.013 ↗
14. 10.1593/neo.12122210.1593/neo.121222 ↗
15. 10.1016/j.canlet.2014.08.02010.1016/j.canlet.2014.08.020 ↗
16. 10.18632/oncotarget.2473710.18632/oncotarget.24737 ↗
17. 10.1038/celldisc.2017.2210.1038/celldisc.2017.22 ↗
18. 10.1016/j.yexcr.2017.08.01110.1016/j.yexcr.2017.08.011 ↗
19. 10.1038/onc.2011.50010.1038/onc.2011.500 ↗
20. 10.1158/0008-5472.CAN-09-199610.1158/0008-5472.CAN-09-1996 ↗
21. 10.1158/0008-5472.CAN-05-013710.1158/0008-5472.CAN-05-0137 ↗
22. 10.1007/s00383-016-3960-810.1007/s00383-016-3960-8 ↗
23. 10.1007/s00428-014-1549-y10.1007/s00428-014-1549-y ↗
24. 10.1016/B978-0-08-046884-6.00223-210.1016/B978-0-08-046884-6.00223-2 ↗
25. 10.3390/ijms1602294210.3390/ijms16022942 ↗
26. 10.1186/bcr280310.1186/bcr2803 ↗
27. 10.5732/cjc.30.037110.5732/cjc.30.0371 ↗
28. 10.1016/j.tips.2004.01.00910.1016/j.tips.2004.01.009 ↗
29. 10.1007/s00432-004-0546-y10.1007/s00432-004-0546-y ↗
30. 10.1016/j.molcel.2004.11.02110.1016/j.molcel.2004.11.021 ↗